Ruan X, Pereda A, Stassi D L, Zeidner D, Summers R G, Jackson M, Shivakumar A, Kakavas S, Staver M J, Donadio S, Katz L
Antibacterial Discovery Research, Abbott Laboratories, Abbott Park, Illinois 60064, USA.
J Bacteriol. 1997 Oct;179(20):6416-25. doi: 10.1128/jb.179.20.6416-6425.1997.
The methylmalonyl coenzyme A (methylmalonyl-CoA)-specific acyltransferase (AT) domains of modules 1 and 2 of the 6-deoxyerythronolide B synthase (DEBS1) of Saccharopolyspora erythraea ER720 were replaced with three heterologous AT domains that are believed, based on sequence comparisons, to be specific for malonyl-CoA. The three substituted AT domains were "Hyg" AT2 from module 2 of a type I polyketide synthase (PKS)-like gene cluster isolated from the rapamycin producer Streptomyces hygroscopicus ATCC 29253, "Ven" AT isolated from a PKS-like gene cluster of the pikromycin producer Streptomyces venezuelae ATCC 15439, and RAPS AT14 from module 14 of the rapamycin PKS gene cluster of S. hygroscopicus ATCC 29253. These changes led to the production of novel erythromycin derivatives by the engineered strains of S. erythraea ER720. Specifically, 12-desmethyl-12-deoxyerythromycin A, which lacks the methyl group at C-12 of the macrolactone ring, was produced by the strains in which the resident AT1 domain was replaced, and 10-desmethylerythromycin A and 10-desmethyl-12-deoxyerythromycin A, both of which lack the methyl group at C-10 of the macrolactone ring, were produced by the recombinant strains in which the resident AT2 domain was replaced. All of the novel erythromycin derivatives exhibited antibiotic activity against Staphylococcus aureus. The production of the erythromycin derivatives through AT replacements confirms the computer predicted substrate specificities of "Hyg" AT2 and "Ven" AT and the substrate specificity of RAPS AT14 deduced from the structure of rapamycin. Moreover, these experiments demonstrate that at least some AT domains of the complete 6-deoxyerythronolide B synthase of S. erythraea can be replaced by functionally related domains from different organisms to make novel, bioactive compounds.
将红球菌属糖多孢菌ER720的6-脱氧红霉内酯B合酶(DEBS1)模块1和模块2中甲基丙二酰辅酶A(methylmalonyl-CoA)特异性酰基转移酶(AT)结构域替换为三个基于序列比较被认为对丙二酰辅酶A具有特异性的异源AT结构域。这三个被替换的AT结构域分别是:从雷帕霉素产生菌吸水链霉菌ATCC 29253分离的I型聚酮合酶(PKS)样基因簇模块2中的“Hyg”AT2;从匹克霉素产生菌委内瑞拉链霉菌ATCC 15439的PKS样基因簇中分离的“Ven”AT;以及吸水链霉菌ATCC 29253雷帕霉素PKS基因簇模块14中的RAPS AT14。这些改变使得工程改造后的红球菌属糖多孢菌ER720菌株产生了新型红霉素衍生物。具体而言,在替换了常驻AT1结构域的菌株中产生了缺乏大环内酯环C-12位甲基的12-去甲基-12-脱氧红霉素A;在替换了常驻AT2结构域的重组菌株中产生了均缺乏大环内酯环C-10位甲基的10-去甲基红霉素A和10-去甲基-12-脱氧红霉素A。所有新型红霉素衍生物均对金黄色葡萄球菌表现出抗生素活性。通过AT替换产生红霉素衍生物证实了计算机预测的“Hyg”AT2和“Ven”AT的底物特异性以及从雷帕霉素结构推导的RAPS AT14的底物特异性。此外,这些实验表明,红球菌属糖多孢菌完整的6-脱氧红霉内酯B合酶的至少一些AT结构域可以被来自不同生物体的功能相关结构域所取代,以制造新型生物活性化合物。